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Writing about endocrine disrupting chemicals (EDCs) including parabens can basically be 
explained by a personal interest and a desire to get more in depth knowledge on the topic. The 
reason for this interest is especially related to the increasing concern of chemicals possession of 
endocrine disrupting effects in humans and animals, and the last 50 years increase in disease 
incidences and prevalences (1). This interest has gradually grown during the last years, as EDCs 
and parabens have received increasing attention in media, and as I have gained more knowledge 
on the topic during the course HEL- 3030 International and Environmental Health. The thesis 
focus on exposures through cosmetics is based on consumers’ extensive and uncritical use of such 
EDC- containing products.  
I find it important to increase knowledge on EDCs, both in terms of more scientific research, and 
informing consumers. Without knowledge it is not possible for consumers to take precautions. 
Precaution is important in terms of protecting the health of individuals and the public. And as 
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A literature study was performed in order to assess and compare evidence of human exposure to 
parabens in cosmetics. The focus of the thesis is on human concentrations, the rate of dermal 
absorption, metabolism and excretion; in order to increase our understanding of human exposures 
to endocrine disrupting chemicals in cosmetics. High detection rates of native and total parabens 
in blood and urine were identified. GMs of native parabens were lower than total paraben levels in 
urine as expected, because parabens need to be conjugated before excreted. More research is 
required to determine medians or means of native parabens in human plasma and serum, as 
disparity exist between median concentrations measured in the two existing studies. Based on 
available evidence it was not possible to conclude on the percentage of dermal absorption, but it is 
indicated that higher exposures to native parabens occur when dermally absorbed in contrary to 
orally. As paraben exposures are widely occurring and parabens have a half- life of less than 24 
hours, regular or constant exposures are identified. Regular or constant exposures do most likely 
occur from the use of cosmetics, which is in conformity with evidence showing both higher 
cosmetic use and higher GMs of parabens among women than men. Elevated paraben exposures 
among women can also cause exposures to the most vulnerable groups; the fetus and breastfeeding 
infant. However, further research is required to investigate to what extent these EDCs with short 
half- lives reach the fetus and the infant through breast milk. Further research is also required to 
investigate effects of parabens in combination with other compounds, the so- called cocktail/ 
mixture effect, as this has been a neglected area in international studies. Based on available 
evidence it can be concluded that strong evidence exists on widely occurring paraben exposures 
among humans.  
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Humans are daily exposed to a number of chemicals simultaneously (3). Some of these chemicals 
are endocrine disrupting chemicals (EDCs), which add to the already high body burden of 
persistent EDCs (4). To reduce human exposures to new EDCs and thereby decrease the potential 
to acquire adverse health effects (5), it is necessary to increase knowledge on chemical exposures.  
Exposures happen through different routes (figure 1), but of increasing concern are exposures to 
EDCs in cosmetics. The concern is related to the extensive and increasing use of such products (6-
8). To assess human exposures to parabens in cosmetics were decided because of their possession 
of estrogenic properties (9, 10), their extensive use in cosmetics (11, 12) and the increasing 
attention they have received in media. As paraben exposures and their potential to cause adverse 
health effects are still debated, it is important to increase knowledge and understanding.  
 
Figure 1: Exposure routes of EDCs. The sources (water, soil, food, air and dust) illustrate pathways for human 





































The objective of this literature study is to assess human exposure to parabens in cosmetic, with a 
particular focus on human concentrations, rate of dermal absorption, metabolism and excretion; 
and by this increasing our understanding of human exposure to EDCs in cosmetics.  
 
3. METHOD AND MATERIALS  
A literature study was performed with the purpose to describe paraben exposures from cosmetics 
in humans, by discussing and comparing evidence. As this is an exposure assessment and not a 
risk assessment, toxicities are not covered. Potential adverse health effects of EDCs and parabens 
are only shortly described in the introduction. As paraben exposures in humans are believed to be 
mainly caused by cosmetic use (9, 14), the discussion is focused on the human concentration, 
dermal absorption, metabolism and excretion of parabens. 
 
3.1 Definitions and clarifications  
Some of the frequently used terms in the thesis can be interpreted subjectively. Definitions and 
clarifications are therefore given to make sure readers interpret the thesis as similar as possible. 
Definitions are shown before potential clarifications:  
 “Exposure” is defined by the International Programme on Chemical Safety (IPCS) (15) as: 
“a concentration or amount of a particular agent that reaches a target organism, system, or (sub) 








“Cosmetics” is defined by the European Commission (EC) (16) as: 
“Any substance or mixture intended to be placed in contact with the external parts of the human 
body (epidermis, hair system, nails, lips and external genital organs) or with the teeth and the 
mucous membranes of the oral cavity with a view exclusively or mainly to cleaning them, 
perfuming them, changing their appearance, protecting them, keeping them in good condition or 
correcting body odours.”  
The Precautionary Principle or Precautionary Approach has several definitions. The European 
Unions (EU) (17) communication on the principle is as follows:  
“The Precautionary Principle applies where scientific evidence is insufficient, inconclusive or 
uncertain and preliminary scientific evaluation indicates that there are reasonable grounds for 
concern that the potentially dangerous effects on the environment, human, animal or plant health 
may be inconsistent with the high level of protection chosen by the EU” (p. 13). The principle aims 
at pre- damage control. Interventions based on the precautionary principle can be initiated in the 
occurrence of morally unacceptable harms, to avoid or reduce them. Such harms are a risk to 
human life or health, severe and permanent, unjust to present or future generations, or imposed 
without concern of the human rights of the people affected (17). An example of a morally 
unacceptable harm can be the addition of an EDC in cosmetics. The precautionary principle is 
included in several international declarations and agreements, like the UN`s 1992 Rio Declaration 
on Environment and Development (17).  
An “exposure” occurs, based on the IPCS (15) definition, when EDCs including parabens are 
absorbed and can be measured in a living organism. For instance, a human is exposed to parabens 
when measurable levels are detected in blood or urine, as native, metabolized or conjugated 
parabens. The definition is based on the fact that no compound can cause adverse health effects if 




Based on the EC (16) definition, “cosmetics” in the thesis include hygiene products as well as 
make- up products, skin creams and lotions, deodorants and perfume, hairspray and shaving 
creams. The decision to use the term “cosmetic” instead of “personal care product” is based on the 
lack of an official definition of “personal care product”, as well as the European Commission`s 
definition of “cosmetics” were satisfactory for use in the thesis.  
There is no official definition of “native paraben”, “paraben metabolite” and “paraben 
conjugate”. In the thesis a native paraben is defined as a non- metabolized or non- conjugated 
paraben. Native parabens can be hydrolyzed into their main metabolite p-hydroxybenzoic acid 
(PHBA) by esterases in human skin (phase one metabolism), or into a glycine, sulfate or 
glucuronide conjugate (phase two metabolism) in the liver and intestines. Glycine, sulfate and 
glucuronide conjugates are conjugated PHBA (9, 18).   
There is not an official definition of limit of detection (LOD) either. The LOD describe the lowest 
concentration of a component that can be detected by an analytical method, and is thereby used to 










3.2 The thesis structure 
The discussion of parabens is found in Chapter 5 and titled “human exposures to parabens”. The 
thesis structure is gradually built- up, so even the unaware reader should be able to get an 
understanding of the thesis topic, and understand the content of the discussion and the conclusion. 
 A rationale is found in Chapter 1 to give an overall explanation of the thesis topic and to explain 
why this topic is important. Chapter 2 state the objective, while Chapter 3 explains how the 
literature study was conducted and which materials were used. This chapter also includes 
definitions and clarifications of terms, and possible limitations in studies on parabens. Chapter 4 
covers the background theory. And it is here explained what EDCs and parabens are, and briefly 
where in the environment and in which products they can be found. It is also briefly explained 
what adverse health effects they can cause and their mechanisms of action in the human body. A 
subchapter on the use of cosmetics is also found here. Chapter 5 gives the information about the 
human concentration of parabens in different matrices. The human concentration is discussed in 
two separate parts, after theme. The first discussion covers dermal absorption and metabolism of 
parabens. Because of overlapping’s between dermal uptake and metabolism, these activities were 
discussed in the same chapter. The second discussion covers the excretion of parabens. A 
subchapter on paraben exposures in the vulnerable groups is located in chapter 5.2.1.  Chapter 6 
is a methodological summary, explaining and studying common methodological challenges in 
studies on parabens. Chapter 7 is reflecting upon effects of parabens in combination with other 
compounds, while the thesis conclusion is found in Chapter 8. The reference list and the 
appendix are found at the end.  
In Appendix A is the example on how literature searches were performed, while literature 
matrices are shown in Appendix B. Matrices were used to make comparisons of paraben 




studies discussed in chapter 5. How these studies were found are explained in the succeeding 
chapter.  
 
3.3 Literature search strategy 
Systematic searches were performed to find all available relevant background theory, and through 
this identify the most relevant papers to discuss in chapter 5. Searches were performed on peer 
reviewed studies using the online search engines PubMed and Scopus. PICO (population, 
intervention, comparison and outcome) was used in the search strategy to find articles specific to 
the topics. Truncation was used to search for different variances of the same word, while boolean 
search was used to make the search more effective. Words where combined with “AND”; “OR” 
was used to find either one of the words searched for; and “NOT” was used to exclude papers not 
relevant to the topic. As a literature study is a dynamic process, searches were done several times 
during the writing process to find theory, and evidence showing an effect or no effect.  Because of 
the large number of searches, it would not be possible to present them in the thesis. However, one 
search strategy is presented in appendix A (including included and excluded studies), to give an 
example on how systematic searches were conducted. This search was conducted to find studies 
on the excretion of parabens.  
 
The search criteria’s were as follows:  
 articles had to be published between 1. January 2010 and 23. April 2013; 
 only human in vivo studies;  
 only single studies (no reviews); 




Reviews were not included in this search to limit the number of studies, because of time and space 
limitations. Since the studies were intended for comparisons, only studies presenting urine 
concentrations as GMs were chosen.  
In general for all searches, search criterias were decided to decrease the number of studies as a 
consequence of time and space limitations, but also to find articles specific to the topic. All studies 
discussed in chapter 5 were published before 23. April 2013. The most recent and relevant studies 
were always preferred, as long as they could be compared. To objectively evaluate the evidence, 




Theory and materials to support or disprove evidence were obtained from different sources. 
Scientific studies were obtained from Scopus, PubMed and Google Scholar. Background theory, 
laws and directives were obtained from reports (national, EU, WHO), web pages, and textbooks. 
EU- reports were used because they have been much debated, and there have been frequent 
meetings about parabens in scientific committees in the EU- system. No unpublished literature 
(grey literature) was used.  
Human studies were preferred over animal and in vitro experiments. This preference was caused 
by the thesis objective of dermal exposures in humans, and because it is debated to what extent we 
can generalize evidence form animal and in vitro studies to humans. Where human studies were 
lacking, animal and in vitro studies were used to indicate evidence. However, the animal study by 
Aubert et al. (20) was also used in the discussion to show differences in animal and human 
evidence.  
In the discussion in chapter 5, scientific studies were always used as primary literature sources. 




articles could not be obtained. Studies on parabens absorption and metabolism (chapter 5.1) are 
presented in literature matrix A and studies on the excretion of parabens (chapter 5.2) are 
presented in matrix B (appendix). Urine paraben concentrations shown in matrix B are all 
unadjusted values. The decision to compare only unadjusted values was made since a higher 
number of articles show unadjusted, than adjusted concentrations. The studies by Wang et al. (21) 
and Frederiksen et al. (22) on the other hand, do not mention or describe urine adjustments. It is 
therefore assumed that values from these studies are unadjusted.  
Endnote was used for managing references, and the program was updated to Endnote X6 in March 
2013. Because numbered references were used, year of publication was not applied, to keep in- 
text references as clear and reader friendly as possible.  
 
3.5 Limitations in available studies 
The limitations presented are general methodological limitations found within studies on parabens 
and other contaminant studies. Such limitations can decrease the reliability of the conclusion, and 
should therefore be introduced.  
Firstly and maybe the most important, are the low number of randomized controlled trials (RCTs). 
Most of the studies used in the thesis have observational designs, and are thereby in the lower 
parts of the evidence pyramid. This is also the case for the animal studies, from which findings are 
difficult to extrapolate to humans. Secondly, many studies have small sample size, which reduce 
the confidence in study findings, and thereby decrease generalizability. Thirdly, several of the 
articles have different study populations (age, gender etc.). Such differences can make findings 
from articles less comparable and thereby less generalizable to other populations. Another 
limitation is the studies use of different limit of detection- levels (LODs). Different LOD- levels 
make findings less comparable, as concentrations also can be found below the LOD. However, 




research paper. Furthermore, more articles measure parabens in urine instead of blood. When 
studying dermal absorption of parabens, blood concentrations are preferred. The preference is 
caused by the fact that parabens to a larger extent are hydrolyzed and conjugated before excreted 
in urine, and that native parabens better reflect dermal exposures.  
Some articles are unclear on how they define parabens, metabolites and conjugates, and whether 
the urine concentrations are specific- gravity or creatinine adjusted. Both these factors can affect 
the findings. However, uncertainty in whether it is native parabens or conjugates that are measured 
is likely to make larger differences in the findings, than unclearness in specific- gravity or 
creatinine adjustments. But at the same time, paraben detections in urine, independent of being 
conjugated or not, indicates exposure. Lastly, it cannot be completely excluded that small 
differences between the studies` results are caused by differences in the methods of detection. 
Evaluations and comparisons of methods have not been conducted as there are currently no quality 
assurance (QA)/ quality control (QC) programs for analyzing parabens in plasma/ urine, as there is 
for POPS (23), and as this is beyond the scope of the thesis. These limitations will be further 













4. EDCs AND COSMETICS 
More than 80 000 chemicals are manufactured and imported into the United States each year (24). 
The production of chemicals has recently reached 400 million tones worldwide, which as a 
consequence leads to increasing amounts of pollution (25). Some chemicals are widely used in for 
instance industry and agriculture, for medical purposes, and are found in consumer products such 
as cosmetics (5). It is estimated that 3000 - 5000 new chemicals are introduced each year, and 
most of the synthetic chemicals today were produced after World War II (24). Many of the 
chemicals have unknown properties, but the increase in hormonally related diseases (13) over the 
last 50 years (1), are suspected to be partly caused by an increasing amount of synthetic chemicals 
(25) (i.e. EDCs). Examples of such hormonally related diseases are breast- (figure 2), prostate- 
and testicular cancer (figure 3), diabetes, obesity and reproductive problems (1).
1
  
An EDC is according to the European Commission (EC) (28):  
"an exogenous substance that causes adverse health effects in an intact organism, or its progeny, 
secondary to changes in endocrine function."  
And a potential EDC is defined by the European Commission (EC) (28) as: 






                                                                    
1 It is important to be cautious when interpreting statistics of disease prevalences and incidences. The last decades  
improve in diagnostics (26), increased reporting’s and over- diagnosing (27) are examples of factors that can affect 






Figure 2: Mammary gland cancer. Age- adjusted incidence (N) in the Nordic countries 1955 - 2010 for women aged 
20 - 79 (29).  
 
                           
 
Figure 3: Prostate- and testicular cancer. Age- adjusted incidence (N) in the Nordic countries 1953 - 2008 in men   





EDCs are a group of heterogeneous substances (1) in which most are synthetic (13). They are 
omnipresent in society and can be found:  
 in industrial products (solvents/lubricants) (1, 4), e.g. polychlorinated biphenyls (PCBs) 
(4); 
 as industrial byproducts, e.g. polybrominated biphenyls (PBBs) and dioxins (4);  
 in plastics (1, 4), e.g. bisphenol A (BPA) (4);  
 as plasticizers, e.g. phthalates (30);  
 as pesticides (4, 31) (fungicides, insecticides, herbicides, rodenticides etc. (31)), e.g.  
methoxychlor, chlorpyrifos and dichlorodiphenyltrichloroethane (DDT) and vinclozolin 
(4);  
 in/ as medications, e.g. DES (4) and parabens (18);  
 in cosmetics, e.g. phthalates, parabens, UV- filters, synthetic polycyclic musks, 
antimicrobials such as triclosan (30), and siloxanes (32);  
 as toxic metals like cadmium (Cd) and lead (Pb) (1). 
According to Zeliger (24), both synthetic and natural hormones are considered endocrine 
disruptors, as they can cause alterations in the endocrine system. Hormones, both synthetic and 
natural, are used as medications, normally causing preferred effects. Looking back into history, it 
is also possible to find examples on endocrine disruptors causing unwanted effects. 
Diethylstilbestrol (DES) for example, was prescribed by physicians between 1948 and 1971 to 
prevent spontaneous abortions, but was found to cause negative health effects in girls and boys 
exposed prenatally. For instance, a reduction in fertility, abnormal pregnancies, immune system 
disorders, depression, early onset of vaginal clear- cell adenocarcinomas and reproductive tract 
cancers was detected in the girls at a higher rate than in the standard population (24). In boys a 




Moreover, DES is suspected to cause hereditary diseases or health effects in third generations 
(34).  
The concerns in relation to EDCs in general, are their possession of estrogenic, androgenic, 
antiestrogenic and antiandrogenic properties (1). Examples of EDCs with estrogenic properties are 
parabens (9, 35) and the UV- filters (35) benzophenone- 1 and phenyl salicylate. Large variations 
have been detected in the potencies of EDCs with estrogenic properties (36). EDCs with 
androgenic properties are less studied than estrogen disrupting chemicals (37). Examples of 
androgenic chemicals are the UV- filters benzophenone- 2 and octyl salicylate, while examples of 
chemicals with antiestrogenic properties are the UV- filters benzophenone- 3 (BP3) and 
homosalate. The UV- filters 4,4- dihydroxy- benzophenone and octocrylene are antiandrogenic 
(36). Some EDCs have a combination of properties, like for example the UV- filter 3- benzylidene 
camphor (3BC), which has shown estrogenic-, antiestrogenic- and antiandrogenic activity in vitro 
in human receptor systems (36). Animal studies have shown EDCs can cause alterations in 
thyroid- and corticoid function, and other metabolic functions (1). This means EDCs can affect 
normal development and reproduction, but also metabolism, growth, fluid balance, cardiovascular 
function and other biological functions involving hormones (30). Hormone- related cancers in 
breasts-, endometrium-, ovary-, testis-, prostate- and thyroid glands are more common in 
industrialized countries, and are still increasing. Hormone- related cancers has also been shown to 
increase in Asian countries, but data from especially Asia, Africa, Central- and South America are 
still in minority (13). Despite EDCs potential to cause adverse health effects, several factors must 
be considered to understand EDCs and their potential risks to human health:  
- Vulnerable groups: humans have critical windows of developmental sensitivity to 
endocrine disruptors including natural- and synthetic hormones (4). The fetus and children 
are considered to be most vulnerable to EDC exposures (38), but also elderly are more 




- Gender: Some chemicals are shown to have greater impacts on men than females, and 
opposite. This can be related to testosterone- and estrogen levels. Few studies exist on this 
topic in humans (24). 
- Latency to health effects: Diseases and symptoms can develop years after exposure. For 
example may exposures during development (pregnancy, infancy, childhood, puberty) be 
manifested first in middle- or old age (4). It can therefore be very difficult to connect the 
exposure with the symptoms. 
- Trans generational: Diseases can occur first in the next generation and thereby cause 
diseases in subsequent generations (4). 
- Mixture effects: Humans are exposed to a number of chemicals simultaneously, and 
combinations of EDCs are likely to increase the overall effect of hormonal influences (3).  
- Dose- response: EDCs can act at very low concentrations, and they may cause stronger 
effects at low- compared to larger- doses (4). EDCs dose- response curves can be standard 
sigmoidal- shaped (monotonic) or for example U- or inverted U- shaped (non- monotonic). 
This means that maximum responses can happen at low- and high doses (U- shaped), or at 
intermediate doses (inverted U- shaped) (13). 
- Genetics: Proneness to EDCs might vary because of genetic polymorphisms (4).  
- Half- life/ persistency: Persistent chemicals (i.e. with long half- lives) can contribute to 
constant exposures over years (4), after one or more exposures, while chemicals with short 
half- lives can contribute to constant exposures when repeatedly exposed through 
cosmetics, food, medications etc.  
As a means to better protect human health and the environment, the EU chemical regulation 
REACH (the Registration, Evaluation, Authorization and Restriction of Chemical Substances) 
(39) has listed 626 EDCs of very high concern (40). REACH was commenced in 2007 and work 
towards earlier and improved identification of chemical properties. This create more 




2012 report by the WHO and United Nations Environmental Program (UNEP) on state of the 
science of EDCs (13), only a small part of the environmental EDCs are known and understood; 
simply the tip of the iceberg (13). 
 
4.1 Persistent EDCs  
Persistent chemicals are, as non- persistent chemicals, both synthetic and naturally occurring. 
Many of the persistent chemicals were and are intentionally produced to have a long half- life, like 
for example PCBs. Others are not intentionally produced, but are for example byproducts of 
different processes, like dioxins. Dioxins and PCBs have a half-life in the human body ranging 
from approximately 1 to 20 years (41). Dioxins and PCBs are persistent organic pollutants (POPs), 
and thereby on the Stockholm Conventions list of chemicals to be eliminated or regulated (42). 
The Stockholm Convention is a global treaty working on protecting human health and the 
ecosystem from POPs. It was adopted in 2001, commenced in 2004 (43), and has today listed 22 
POPs for elimination or control (42). POPs affect humans and biota negatively because of several 
factors: 
 they are toxic, even at small concentrations (44);  
 they have high persistence (44) (i.e. persist in the environment for years); 
 they bio- accumulates in the food chain (44) (i.e. the higher up in the food chain, the 
higher concentrations can be detected); 
 they are lipophilic and accumulate in living organisms fatty tissues (44);  
 they can be detected in remote areas where no industry exists (44), as in the Arctic, 






Some persistent chemicals can cause detrimental effects in human- and animal health and in the 
environment (4). Already in the 1940`s, Rachel Carson raised concern regarding the use of 
pesticides. She manifested the detrimental effects pesticides, and especially DDT, had on animals 
and the environment in her book Silent Spring published in 1962 (45). Examples of other 
persistent EDCs of concern are chlordanes, which are an organochlorine pesticide like DDT, and 
furans that are byproducts of different chemical processes or waste incineration as dioxins (44).  
Bans and regulations of persistent chemicals are shown to have a positive effect decreasing 
exposures. For example, after the banning of DDT in developed countries (44) from the 1970s 
(46), a decrease in the body burdens of DDT has been observed in exposed populations. However, 
due to DDTs persistency, it can still be detected in for instance human breast milk (46). Lipophilic 
chemicals like DDT (46) and toxic metals like lead (Pb), cadmium (Cd) and arsenic (As) can be 
transferred from the mother to the fetus (47) and infant. High positive correlations have been 
detected between organochlorine pollutants and maternal fat tissue, plasma, cord blood and breast 
milk (48, 49). During breastfeeding, the mother`s body burden of organochlorine pollutants 
decrease (50), and the body burden of these substances will be lower in women who have 
breastfed, compared to those who have not (51).  
Even though many of the environmental chemicals are ubiquitous and cannot be avoided, it is 
possible to reduce exposures to certain EDCs (both persistent- and not- persistent chemicals). One 










4.2 EDCs in cosmetics 
Despite of the European Union (EU) (52) law that states the use of cosmetics shall not pose a 
threat to human health, under normal or reasonably predictable conditions, a wide range of 
different EDCs and potential EDCs are used as ingredients in cosmetic products. Examples are: 
 Parabens (30, 53); 
 UV- filters, e.g benzophenone- 1, benzophenone- 3 and octinoxate (1, 30, 53, 54); 
 Synthetic musks and other fragrance compounds (30, 53); 
 Antimicrobials, e.g. triclosan (30, 53); 
 Cyclosiloxanes: octamethylcyclotetrasiloxane (D4), decamethylcyclopentasiloxane (D5) 
and dodecamethylcyclohexasiloxane (D6) (53); 
 Bisphenol- A (BPA) (1, 53); 
 Alkylphenols, e.g. nonylphenols and octylphenol (53, 55); 
 Glycol ethers (53). 
Chemicals are used in cosmetics as preservatives or solubilizes, as fragrances, colorants and UV- 
protection. The substances are mostly non- persistent, but traces of for instance the persistent and 
toxic metal lead (Pb) have been detected at trace levels in at least lipstick. Despite the low 
concentrations identified (56, 57), lead may accumulate and add to the body burden of EDCs. 
Lead, BPA, musk xylene, the siloxsane D5 and triclosan are on the Norwegian Climate and 
Pollution Agency’s (KLIF) “high concern- list”, and are to be reduced or forbidden by 2020. The 
restriction or ban was decided because of the chemicals properties or potential to cause adverse 
effects in humans and/ or the environment (58). Other EDCs in cosmetics that are listed by KLIF 
as concerning, are diethyl phthalate, the siloxsane D4, the UV- filter isotiazoliner 4- 
Methylbenzylidene camphor, and lastly, toluene/ methylbenzene, which are found in nail polish 




connect these health effects with the chemicals, as humans are regularly exposed over years and it 
can take years before negative health effects occur (60).  
The safety of cosmetics have for many years been tested by conducting animal studies, even 
though human studies produce more reliable results. But now, as a result of the European 
Commission`s (61) animal testing ban on cosmetics, the cosmetic industry must find equally good 
alternatives to be able to safety assure cosmetic ingredients and products. The directive came fully 
into force in March 2013, and prohibits animal testing of finished cosmetic products and cosmetic 
ingredients within the EU. The directive does also include a marketing ban of such products 
within the EU (61). A result of this directive can be a reduction in cosmetic innovations, where it 
can become harder for companies to find substitutes to EDCs in their products.  
Consumers have a freedom to choose what products to buy. But not all product ingredients are 
always labeled. UV- filters, phthalates and parabens were for instance not labeled on some of the 
products tested by Dodson et al. (53). However, because of the EU- regulation (EC) no 1223/2009 
(52), declaring that ingredients must be documented on the product, it is likely most chemicals are 
printed on the label. This also the case in Norway, because of the Norwegian Cosmetic 
Regulation`s implementation of the European Commission’s regulation. The only difference in 
these regulations concern pharmacological active ingredients allowed in cosmetics (62). However, 
impurities from raw materials and lower concentrations of technical materials not present in the 
final product, are not required to be documented on the product (52). Neither is every single 
fragrance chemical, where it is permitted to only print “parfum” or “aroma” on the label (52). As a 
consequence it is more difficult for consumers to identify all of the products ingredients, and thus 
be able to avoid exposures.  
In summary, many different EDCs and potential EDCs are used as ingredients in cosmetic 




forbidden by 2020. As cosmetics can contain EDCs and potential EDCs, public information and 
high consumer awareness are required.  
  
4.3 EDCs mechanisms of action in the human body 
 
The factors that cause diseases are many, but non- communicable diseases are usually caused by a 
combination of genetic- and environmental factors. Environmental chemicals can affect the 
hormone system (figure 4) through different mechanisms. Firstly, by affecting hormone receptors 
and receptor mechanisms directly, or by acting directly on specific proteins that regulate hormone 
delivery to the receptor. In the last mechanism mentioned can the protein be involved in hormone 
production (e.g. aromatase), it can be a transporter (e.g. sodium/ iodide symporter) or a carrier 
protein (e.g. cortisol binding protein). An EDC can also block the hormone- synthesis, making 
hormone concentrations rise or fall (13).  
Hormones bind to and act on specific proteins, i.e. receptors, and cause actions (13) like 
alterations in developmental and reproductive mechanisms (25). Hormones can act by one 
specific- or several receptors. Estrogens for example act by estrogen receptor alpha (ERα), 
estrogen receptor beta (ERβ) and by distinct membrane receptors on certain cells. The numbers of 
receptors estrogens act by are unknown. Testosterone on the other hand, acts only by one receptor, 
the androgen receptor (AR) (13). Hormones act largely through membrane bound receptors that 
respond to peptide hormones (e.g. insulin), and through nuclear receptors (NRs) activated by 
interaction with lipophilic hormones (25) (e.g. steroid- and thyroid hormones) (13). The main 
endocrine systems that can be altered by EDCs are the estrogen, the androgen and the thyroid ones 
(49). Action through NRs is one of the EDCs main ways of action (25). When hormones act by 
NRs, new proteins are developed as a result of the hormone and receptor binding to particular 
areas of the DNA, regulating the development of gene transcription. Steroids like estrogens and 




many xenobiotics, can act through specific NRs, which are likely to disturb or modulate 
downstream gene expression. One example is EDCs causing alterations in the mechanisms of the 
ER and/or AR, altering the normal action of estrogens- and androgens ligands. Reproductive and 
developmental alterations caused by EDCs, are suspected to stem from this mechanism (25). 
EDCs can also act through for example non- steroid receptors like neurotransmitter receptors 
(serotonin-, dopamine- and norepinephrine receptors), but also through orphan receptors like aryl 
hydrocarbon receptors, and enzymatic routes affecting steroid biosynthesis and/or metabolism (1).  
EDCs can act as both agonists and antagonists, and may impact hormone secretion, biological 
half- life or alter the feedback relationships that exist in the hypothalamic- pituitary target organ 
systems like the gonadal, thyroid or adrenal ones (30). Thyroid disrupting chemicals, like PCBs 
(4), can especially cause adverse health effects in humans exposed in sensitive periods of life. This 
is because these hormones are important in brain maturation, cognitive growth and behavior, and 
development (5). Pregnant women, fetuses, premature children, infants and toddlers are more 
vulnerable to permanent effects on neurodevelopment, while exposures to thyroid disruptors in 
older children and adolescents primarily cause negative effects associated with growth and 
reproductive development (63). Adverse effects related to thyroid hormones can be caused by 
EDCs binding to thyroid hormone receptors (TR) on target cells, decreasing bioavailability of 
thyroid hormones to the NRs. Certain EDCs can act by the TR, as agonist or antagonist, or 
indirectly by regulating expression of the TR- genes. Normal development of the central nervous 





Figure 4: Human hormones. After being created in specific cells in different glands and tissues, hormone molecules 
are transported through the blood, and acts on target tissues. Figure reused with publishers permission (13).  
 
Development of different cancers has also been linked to EDCs. Alterations in ERs caused by 
EDCs have been associated with breast- , lung- , kidney- , brain- , pancreas- and reproductive 




alterations in the masculinization process of the male fetus, triggering development of low sperm 
count, testis cancer, hypospadias and cryptorchidism (15, 51). It is an assumption that breast 
cancer can be triggered by EDCs, following alterations in ERs, as estrogens can stimulate growth, 
progression and metastasis of breast cancer (13). Parabens are an example of a group chemicals 
that possess both estrogenic (9) and antiandrogenic effects (65, 66), acting as ER agonists and AR 
antagonists (10). However, research also shows EDCs may have an impact on metabolic 
alterations, for example in the development of obesity. Obesity is on the other hand linked with 
metabolic syndrome, diabetes type 2, liver disease, cardiovascular- and pulmonary diseases, 
psychological- and social problems, reproductive defects and some types of cancer (25). After all, 
there is still a lack of knowledge on EDCs mechanisms of action in the body and their long- term 
effects.  
 
4.4 The use of cosmetics  
Cosmetics are not a new invention. Already 10 000 BC Egyptians used fragranced oils and 
ointments to clean themselves, soften their skin and cover body odors. Essential oils were vital in 
their belief: "cleanliness is godliness". Hygiene was important (67). Trends have changed through 
time, and certain cosmetic trends have not always been so fortunate. From the middle ages, lead 
and arsenic were used for skin- whitening, as it was more status to be pale as the aristocrats than 
sun- tanned like the lower class workers working outdoors (67). Cosmetics are today used for  
different reasons, and even though fragrances and skin paling ointments still are widely used, 
ingredients have changed; for good and for bad. 
Today cosmetics are used for hygiene, as colorants, fragrance, protection and appearance. 
Products are applied random or regularly every day, to smaller or larger areas of the body and are 
often used over years. Exposed parts of the body are the skin, hair and scalp, lips, oral-, ocular- 
and vaginal mucosae, axillae, nails (68) and lungs (60). Exposures happen orally, dermally and by 




cosmetics like deodorant, facial cream and mascara every day, while 54.7 % of the 332 women in 
the study by Sandanger et al. (69) was shown to use facial cream once every day. Sandanger et al. 
(69) also detected 45 % of the population to apply cream on the whole body once or more every 
day. Even though the cosmetic demand is already high, it is still increasing (70). The total 
cosmetic market value increased in Europe (27 EU countries + Norway and Switzerland) with 2.2 
% in 2010 compared to 2009. In Norway only, it increased with 1.8 % in the same time period 
(values based on retail sales prices) (8).  
The use of cosmetics is very individual and large- scale population- based studies, like the 
Norwegian Women and Cancer study (NOWAC) (71), are therefore needed to increase knowledge 
on exposures to chemicals in such products. Yet, not much research exists on the usage patterns of 
cosmetics. Two studies did however study gender- and age- differences (6, 7), and both identified 
a higher prevalence and frequency of cosmetic use, for most cosmetic products, among women 
compared to men. Still, according to one of the studies, men had a higher use frequency for at least 
shampoo and bath gel (6). According to Elsner (2012) (72), the number of men using cosmetic 
products is increasing. However, cosmetics are also used by groups considered more sensitive to 
EDCs. For instance, a frequent use of cosmetics has been reported in infants and children, where 
girls were shown to have a higher use frequency than boys (6). The same study did also 
investigate correlations of cosmetic use between parents and children (6). When interpreting the 
spearman correlation coefficients (rs) (non- parametric test) as suggested by Pallant et al. (2007) 
(73), moderate correlations (p = < 0.05) were detected for different cosmetic products (6). Another 
study showed mostly low and moderate correlations (p = < 0.01) when investigating Spearman 
correlations between mothers and children’s urine concentrations of phthalates, phenols and 
parabens. High correlations where only detected for benzophenone- 3 and triclosan (p = < 0.01) 




Humans are exposed to EDCs through different types of cosmetics, but some cosmetics cause a 
higher exposure to EDCs than others. Shower gel, sunscreen, body lotion etc. gives a higher 
exposure than for example mascara and eyeliner, as they are applicated to larger areas of the body 
(75). The daily exposure (mg/kg bw/day) of individual products have been calculated to be 1.12 
mg and 0.57 mg for liquid body soap and cleansing products, respectively; and 268.33 mg and 
17.43 mg for body lotion and roll- on antiperspirant, respectively (76). This shows that leave- on 
products contributes to a larger relative daily exposure than wash- off products. And, the larger the 
area applicated the larger is the exposure. To be able to assess risks of EDC- exposure through 
cosmetics adequately, it is necessary to map usage patterns and to use biomonitoring. Usage 
patterns are mapped by identifying exposure history and by for instance using questionnaires, 
while biomonitoring can be conducted by measuring chemical concentrations in blood and urine.  
In summary, usage patterns of cosmetics are very individual, but some population groups have a 
higher use than others. Studies indicate a higher use among women than men; and a higher use 
among girls than boys (6). Correlations do however indicate differences between chemical 
exposures in children and their parents (74). As some populations use more cosmetics than others, 
they are likely more exposed to EDCs. The use of cosmetics in more sensitive groups is however 












Parabens, the alkyl esters of p- hydroxybenzoic acids (PHBA) (68), are a group of non- persistent 
chemicals (74) used individually or in mixtures to reach preferred antimicrobial- and preservative 
effects. They are especially effective against molds and yeasts, and are widely (18) used because 
of their antimicrobial-, and relatively non- irritating- and non- sensitizing properties. Parabens 
have low acute toxicity (9, 68, 77), but have been associated with allergy. They also have low 
cost, (9) and are pH-stable (i.e. they help in preventing too rapid product degradation) (68, 77). 
Short chained parabens are more hydrophilic and the long chained are more lipophilic (figure 5). 
When the chain length of the paraben increases, the resistance to hydrolysis and antimicrobial 
activity increase (9), but water solubility decrease. As a consequence, methylparaben (MP) and 
propylparaben (PP), which have shorter chains, are the ones most used in cosmetics (9). MP and 
PP are however also preferred for use in foods (68, 77). MP, PP, butylparaben (BP), ethylparaben 
(EP), heptyl- (HP) and benzylparaben (BzP), isopropyl- and isobutylparaben are homologous (30, 






Figure 5: The chemical structures of parabens.  The paraben metabolite p- hydroxybenzoic acid (PHBA) develops 
after hydrolysis of the ester linkage. PHBA can conjugate into p- hydroxyhippuric acid (PHHA). Figure reused with 
publishers permission (18). 
 
The use of parabens have caused concern due to their possession of estrogenic- (9) and 
antiandrogenic properties (65, 66) (i.e. they can act as ER agonists and AR antagonists). Parabens 
may affect health at lower concentrations and more precise than non- receptor mediated 
mechanisms, because of their capability binding to ERs (69). Several studies, both in vitro and in 
vivo, have demonstrated parabens disruptive effects in physiologically important mechanisms. The 




thereafter regulate gene expression and cell growth in estrogen- responsive cells through ER 
mediated mechanisms (figure 6). But parabens do also have the potential to antagonize AR– 
mediated effects in androgen- responsive cells, and to behave as sulfotransferase enzyme (SULTs) 
inhibitors (10) and act on the regulation of steroids (61). In fact, both in vitro and in vivo assays 
show all common native parabens possess estrogenic effects (10). And the longer paraben chain, 
from MP to n- BP, the larger are these effects (9, 78). A higher estrogenic effect is also associated 
with branching in the alkyl chain, from n- PP to isopropylparaben (79), and n- BP to 
isobutylparaben (80). However, the estrogenic effects have been detected to be 10 000 to 100 000- 
fold weaker than natural 17β- estradiol, after subcutaneous administration to rats (78). According 
to Darbre et al. (80), isobutylparaben has the strongest estrogenic effect. PHBA, parabens main 
metabolite, have a weaker estrogenic effect than native parabens (10). Despite unclear 
estrogenicity of glycine-, sulfate- and glucuronide conjugates, the Scientific Committee on 
Consumer Safety (SCCS) (81) has concluded that they are most likely not estrogenic. This 
conclusion was mainly based on the fact that steroid conjugates themselves cause no effect at the 
receptor (81). In theory, as a consequence of parabens estrogenic- and antiandrogenic effects, 
parabens may cause diseases related to the endocrine system. Reproductive diseases and endocrine 
cancers have been of special concern. For instance, parabens have been detected in larger 
concentrations in the axilla area compared to the lateral, mid and medial side of the breast, and a 
link between parabens in underarm cosmetics and breast cancer has been suggested (82). No 
association, however, has been made between single parabens and breast cancer. A recent study by 
Charles and Darbre (83) on the other hand, showed that combinations of parabens in human breast 
tissues are large enough to stimulate proliferation of MCF- 7 breast cancer cells. In some tissue 
samples, all single parabens measured were detected at concentrations below “no- observed- 







Figure 6: Parabens molecular pathways in cells.  As parabens are EDCs, they can act as ER- agonists, as AR-   
antagonists or as inhibitors of SULTs. But they can also disturb lysosomal and mitochondrial mechanisms, cause 
DNA damage, and amplify UVB- induced damage through production of reactive oxygen species (ROS) and nitric 
oxide (NO). Figure reused with publishers permission (10). 
 
When considering reproductive diseases, Oishi (65, 66) reported decreased sperm production and 
adverse effects on testosterone- concentrations after oral exposures to PP and BP in young male 
rats. These adverse effects are assumed to be caused by parabens estrogenic activity. It is however 
also likely the effects were caused by anti- androgenic mechanisms (10), as several parabens are 
shown to bind to human ARs and antagonize the effects of testosterone on reporter gene 
expression (63). A similar study by Oishi (84) on the other hand, did not observe any adverse 
effects after oral exposure of MP and EP, and neither did the study by Hoberman et al. (85) where 
young rats where fed with MP and BP. It is however likely that the differences in observed effects 
were caused by exposures to parabens with different estrogenic properties. PP and BP are as a 
matter of fact more estrogenic than MP and EP (9, 78).  
Recent studies have also suggested parabens to be genotoxic, which indicate parabens may 
influence the development of malignant melanoma through both genotoxic- and estrogenic 
activity (10). However, very little is known about this topic. And yet, there is still a lack of 




The main source of parabens is expected to be through cosmetics (14), and based on this the SCCS 
(86) has estimated the systemic exposure dose (SED) of native BP in cosmetics to be 0.043 mg/kg 
bw/day. Calculations shown below: 
Maximum concentration of single parabens: 0.4 %  
Cumulative exposure of cosmetics added parabens/ day: 17.4 g
2
 
Maximum dermal absorption: 3.7 % 
Body weight (bw): 60 kg 
 
    
            
   
    
   
   
     
                             
 
The margin of safety (MoS), which is the threshold between safety and risk, has been estimated by 
using a “no– observed– effect- level” (NOEL) of 2.0 mg/kg bw/day. The NOEL is based on 
subcutaneous injections of BP to neonatal rats (87). The calculation of MoS: 
MoS = NOEL / SED = 2.0 / 0.04292 = 46.59 ≈ 46.6 
As a result of this estimate, the SCCS has recommended to reduce the maximum concentration of 
BP in cosmetics to 0.19 %. Only then will the MoS be kept over 100 (86), which is the WHO`s 
limit to conclude with the safety of a chemical (88).  
The calculation has however been adjusted for children. For a 3 months old child weighing 5.3 kg 
and with a body surface of 0.31m
2
, cumulative exposure to leave- on products a day would be  
17.4 g * 0.31 m
2
 / 1.75 m
2 
= 3.08 g/day.  
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NOEL = 2.0 mg/kg bw/day  
MoS = NOEL / SED = 2.0 /        = 49 
However, data on the amount of cosmetics children are exposed to must be obtained, as it is not 
realistic that children are exposed to as many products as adults.  
 
4.5.1 Paraben use and regulations 
Parabens were first used in pharmaceuticals in the 1920s (89). Today parabens are used in 
pharmaceuticals, food- (9), and consumer products such as detergents (12) and cosmetics (9). 
Humans are therefore exposed through inhalation, ingestion and dermal absorption (60). Even 
though exposures happen through different products and routes, the main expected source of 
exposure is through cosmetics (14). The total aggregate exposure from food is assumed to be less 
than 4 - 5 % (9, 14). Inhalation and digestion are therefore considered less important sources. In 
1981, producer reporting’s to the U.S. FDA identified parabens in 13 282 cosmetic formulations 
(11). This number is large, but it is likely to be underestimated as the reporting’s where 
voluntarily. The number may however not be generalizable to the European population as the 
number is based on U.S. producers. A study from 2008 on the other hand, investigated chemical 
concentrations in 204 cosmetic products bought from stores in Stockholm (12). 44 % of the 
products tested contained parabens. MP was detected in 41 % of the products and was thereby 
most commonly observed. PP was detected in 25 % of the products, EP in 22 %, BP in 14 % and 
isobutylparaben in 13 % of the products (12). Since the Norwegian Cosmetic Regulation 
implements the European Cosmetic Regulation (EC) no 1223/2009, and Sweden is an EU member 
state, these results can most likely be generalized to Norway (62, 90).  
The EU (52) has set the maximum total concentration of parabens permitted in cosmetics to 0.8 % 




paraben to 0.4 % (regulation (EC) no 1223/2009). The safety of parabens has been evaluated 
several times since 2005. And because of parabens potential risks to cause adverse health effects 
in infants and children (60, 91), the Danish Government banned PP, isopropyl-, BP and isobutyl- 
parabens in cosmetics for children up to three years of age in March 2011 (81). The banning was 
meant as a precautionary measure, and was implemented by Denmark as the only country within 
the EU (91). After the Danish Governments banning, the SCCS published a clarification of the 
previous published opinion from 2010 (86). The clarification stated that the use of cosmetics 
containing parabens in general is safe, as long as the concentrations added are no more than the 
maximum permitted levels. An exception, however, was made for certain products used in the 
nappy area. This result was based on their calculation of MoS, which they consider conservative 
(81). In May this year (2013) a new opinion was published, stating the concentrations of parabens 
allowed in cosmetics are still considered safe for humans. But, as a result of the MoS, the SCCS 
has recommended to reduce the maximum concentration of PP and BP in cosmetics from 0.4 % to 
0.19 %. The recommendation was grounded on the absence of adequate knowledge on dermally 
absorbed parabens in rats compared to humans. But still, the risks of isopropyl-, isobutyl-, benzyl-, 
pentyl- and phenyl parabens are unidentified (86).   
In summary, parabens are widely used in cosmetics, and the main expected source of exposure is 
through cosmetics (14). Maximum permitted level of parabens in cosmetics are 0.8 % for a 
combination of native parabens, and 0.4 % for single native parabens (52). The SCCS considers 
their maximum permitted level of concentration to be safe, but recommend reducing the maximum 
total concentration of PP and BP to 0.19 % (86). The safety of paraben exposures to the vulnerable 









5. HUMAN EXPOSURES TO PARABENS  
5.1 Blood metabolism 
Human and animal in vivo and in vitro studies have been performed to investigate dermal 
absorption and metabolism of parabens. In this chapter, state of the art knowledge on dermal 
absorption and metabolism of parabens in plasma and serum is compared and discussed. Despite 
urine as such can be used as matrix, blood is preferred. The reason is because native parabens, 
which reflect dermal compared to oral exposures most (22), are found to be less conjugated in 
blood than in urine, and that parabens in blood are more directly linked to potential effects. So far, 
it has been debate on how high percentage of native parabens is absorbed. But what is known is 
that parabens are dermally absorbed and metabolized by esterases in the skin. When orally 
absorbed they are mainly metabolized by esterases in liver and intestine (18). And as parabens are 
more hydrolyzed in human liver than in human skin (92), more systemic available native parabens 
are observed when dermally absorbed compared to when orally absorbed (22).  
Mostly animal and in vitro studies have been conducted to identify maximum dermal absorption 
rates of parabens in humans. According to a study by Cowan- Ellsberry et al. (14), 80 % was 
chosen as a conservative measure of the maximum amount of native parabens and their 
metabolites to be dermally absorbed. The estimate was based on mostly in vitro studies, where 
dermal uptake ranged from 15 % - 75 % (14). Also another in vitro study on native parabens and 
their metabolites found the minimum concentration dermally absorbed to be 15 % (18). Their 
maximum value of 57 % on the other hand (18), was 18 % lower than what observed by Cowan- 
Ellsberry et al. (14). Conversely did a study on rats (20) observe 0.5 % - 9 % native MP, PP and 
BP and their metabolites to be systemically available. This is even lower values than observed in 
the two previous studies (14, 18). The latter study`s estimates of systemic availability was 
considered worst possible case of the applied dose (20), and the higher permeability of topical 




concentrations were however measured in urine and faeces (20), in contrary to the two other 
studies measurements in blood and skin (14, 18). One reason for the much lower concentrations 
observed in the animal study (20), could be differences in the metabolism of rats and humans or 
the in vitro models. Data for such conversions is still lacking. As there is a shortage of proper 
human studies on the rate of dermal absorption, the SCCS (86) decided to use 3.7 % as a measure 
of maximum dermal absorption of native BP. The conclusion was based on three in vitro studies 
(94-96), where the estimate was calculated from the average dermal absorption of 37 %, measured 
in split- thickness skin (95). A correction factor of 10 was used to correct for skin metabolism as 
detected in full thickness skin experiments (94, 96). However, because in vitro and animal studies 
cannot be directly generalized to humans, they can only be used as indications on exposure.  
RCT is the best study design when studying exposures, but only two RCTs, conducted by Janjua 
et al. (97, 98), exist on parabens in humans. Janjua et al. (97) investigated 24 hour urine excretion 
level of total BP after dermal application, and observed a mean recovery of only 0.32 %. This is a 
small percentage considering the large dose of BP applied (2 %) (97). However, as sulphated 
parabens have been shown to be the main conjugate of at least MP and PP (99), and PHBA have 
been shown to be the main metabolite of parabens in general (9, 18), it is likely the result of 0.32 
% is an underestimation as neither glucuronidated conjugates nor PHBA were measured. Since 
lipid solubilizes in creams can decrease skin absorption (100), this could be another reason for the 
low percentage of recovery. The amount of BP applicated on the subjects is nevertheless not 
realistic compared to a real life context  (97). However, as native parabens are less conjugated in 
blood than urine, more native BP would have been detected if blood was used as matrix.  
When studying dermal absorption of parabens, it is important to consider differences in paraben 
uptake in whole and damaged skin. As damaged skin is more common in the nappy area of infants 
compared to adult skin, it is especially important that exposures are known in order to conduct risk 




age are in risk when leave- on products containing parabens are applied to the nappy area. The 
assumption of risk is based on infant’s immature metabolism and the likelihood of damaged skin 
in this area (101). Research on paraben exposures through damaged skin is in general lacking, but 
one study observed an increase in systemic availability of MP and PHBA in damaged skin, using a 
pig ear model (102). Despite the percentage of parabens dermally absorbed in general is unknown, 
measurements of native and total parabens can be used to show exposures.  
Three studies have measured native paraben concentrations in human plasma or serum (69, 98, 
103), but there is only one RCT (98). Janjua et al. (98) conducted a crossover experimental study 
on 26 Danish men aged 21 – 36, and proved that native BP is systemically absorbed after dermal 
application. Before whole- body application of a cream containing 2 % BP, 2 % diethyl phthalate 
(DEP) and 2 % dibutyl phthalate (DBP), untraceable or a maximum of 1.0 µg/L BP could be 
detected in serum. Three hours after the first application, BP reached an average (± standard error 
of the mean, SEM) concentration of 135 (± 11) µg/L. At peak concentration, 0.81 mg of native BP 
was calculated to be present in the circulatory system. 0.81 mg was distinguished by multiplying 
the mean peak BP concentration with the estimated average blood volume of an adult man: 0.135 
µg/L x 6 L = 0.81 mg. Mean (± SEM) serum levels of BP decreased to 18 (± 3) µg/L after 24 
hours, before the second application (98). The observed concentration of native parabens in this 
study can however be overestimated. High concentrations of all three chemicals applied, can cause 
saturation of skin esterases, and thereby cause higher concentrations of native parabens (86). 
Because 0.4 % is the maximum permitted concentration of single parabens in one product within 
the EU (52), 2 % BP in one product is unrealistically high. Because cosmetics usually do not 
contain that much paraben and 2 % phthalates, saturation of skin esterases cannot happen to the 





Sandanger et al. (69) measured native MP, EP and PP in plasma from 332 postmenopausal women 
with an average age of 55 years. Native MP was detected with a median concentration of 9.4 
ng/ml, EP < 3 ng/ml and PP < 2 ng/ml (p = < 0.001). 95 % of the subjects reported applying lotion 
to 50 – 100 % of the body each day
3
. Median (range) plasma concentration of MP, EP and PP 
were in this group 12.8 ng/ml (3.5 – 129.3), 1.5 ng/ml (1.5 – 45.9) and 1.0 ng/ml (1.0 – 43.9), 
respectively (p = < 0.001). For EP and PP this were the highest concentrations detected, compared 
to any of the other groups. Maximum concentration of MP (142.7 ng/ml) was on the other hand 
detected in the group of those applying cream to “150 – 200 %” of their body each day (equivalent 
to covering their whole body 1.5 – 2 times per day). A significant association was observed 
between the use of cream and paraben plasma concentrations (69). Ye et al. (103) on the other 
hand, observed lower concentrations of native MP, PP and EP than Sandanger et al. (69). The 
respective median (range) values of MP and PP were as follows: 0.2 (< 0.1 - 9.8) ng/ml and < 0.2 
(< 0.2 - 2.3) ng/ml. EP was not detected (103), which may indicate a lower use of EP in cosmetics. 
The detection rates of MP and PP were 60 % and 47 %, respectively (103). In comparison, 
Sandanger et al. (69) detected MP, PP and EP in 63 %, 29 % and 22 % of the samples.  
On the contrary, not all in vivo experimental animal studies have detected native parabens after 
dermal application (18). Aubert et al. (20) for instance, did not detect native parabens in male or 
female rats after oral or dermal administration of 100 mg/kg MP, PP and BP, or after 
subcutaneous administration of 100 mg/kg BP (20). This was however expected as no in vivo 
study yet has detected native parabens in rat serum. As also suggested in other studies (18), that 
may be related to an easier hydrolyzation of parabens in rats than in humans. Because of 
differences in the absorption and metabolism of humans and rats, results from rat studies cannot 
be directly extrapolated to humans. Methods of converting results from rat studies to humans must 
first be produced and validated. According to the SCCS (86) it is a shortage of data for the 
conversion from rat to human absorption (86). As long as such data do not exist, results from rat 
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studies can only be used as indications before further studies on humans, if ethically and medically 
correct. To summarize, even though native parabens have not been detected in rat serum in in vivo 
studies, Janjua et al. (98), Sandanger et al. (69) and Ye et al. (103) proved humans are widely 
exposed to native parabens.  
Dermal exposures of parabens can also be investigated by measuring total concentrations of 
parabens in blood, as total levels include both native parabens and conjugates. But as long as 
native and conjugate levels not are presented separately, paraben metabolism cannot be studied. 
Total concentrations of parabens in blood were measured in two studies (22, 103). EP and PP were 
detected at very low concentrations in both (22, 103), but median concentration MP was identified 
by Ye et al. (103) to be over seven times higher than the one observed by Frederiksen et al. (22). 
Ye et al. (103) did also detect higher percentages of MP and PP than EP, which draw parallels to 
the detections of conjugates. Mean percentages of conjugated MP, EP and PP were 90 %, 100 % 
and 87 %, respectively (103). The high levels of conjugates are similar to another study (18), 
where  over 90 % of the parabens administered to animals were found to be present as conjugates.  
Even less studies exist on human concentrations of PHBA compared to paraben conjugates. The 
few studies can be related to PHBAs reduced usefulness as a biomarker of exposure. PHBA are 
mainly produced in the body after metabolism of native parabens, and is non- specific (21). As 
with conjugates, if higher concentrations of native parabens than PHBA are detected, it is more 
likely the uptake occurred from dermal application. Findings from Wang et al. (21) for instance, 
indicate a dermal exposure route in contrast to an oral.  
What determines the percentage of dermal absorption, and the level of paraben exposure, are most 
likely to be the use of cosmetics, the paraben content in the cosmetics applied and biological 
mechanisms. As mentioned in the background theory, there are large individual variations in the 
frequency of cosmetic use, while paraben content in cosmetics is determined by country and union 




EU Cosmetic Regulation (52), while the U.S. FDA (104) do not regulate the use. Based on 
available evidence it is more likely that the differences in paraben exposures are caused by 
variations in the use of cosmetics and by products paraben content compared to differences in 
biological mechanisms regulating paraben absorption and metabolism.  
In conclusion, findings from the available evidence show native parabens were detected in 
approximately 60 % of the samples, while the one study showing detection rates of total parabens 
observed MP in 100 % of the samples. More research are required to determine median rates of 
native parabens in human plasma and serum, as there is a lack of studies, and disparity exist 
between median concentrations measured in the two existing studies. Based on available evidence 
it is not possible to conclude with the rate of dermal absorption. More and improved RCTs are 
required. More studies are especially required on native parabens in plasma and serum, as they are 
more directly linked to potential effects. And as there is also a lack of studies on differences in 
paraben uptake in whole and damaged skin, further research is needed to determine the risks of 
applying parabens to especially the nappy area of infants. Evidence show animal studies should 














5.2 Excretion of parabens 
This chapter investigates exposures of native and total parabens, by comparing and discussing 
state of the art knowledge on paraben concentrations in urine. It is expected to find lower 
concentrations of native parabens in urine compared to blood.  
The measure of native parabens in urine shows the extent of paraben metabolism and excretion. 
As expected, few studies have used urine as matrix when measuring native parabens, but among 
the few that have are Shirai et al. (64) and Wang et al. (21). They both measured urine 
concentrations of native MP, EP and PP. The highest GMs of all three parabens were observed by 
Shirai et al. (64). But, even though MP, EP and PP were detected with GMs (range) of only 6.99 
ng/ml (< 0.57 – 544 ng/ml), 0.62 ng/ml (< 0.47 - 63.2 ng/ml) and 0.60 ng/ml (< 0.48 – 14.3 
ng/ml), respectively, maximum values were considerably higher. The maximum values are higher 
than the 95
th
 percentiles in the populations investigated by Wang et al. (21), except from PP in 
Chinese adults (21). Variations in ranges and percentiles reflect individual differences in 
exposures. Despite of the high concentrations detected by Shirai et al. (64), the detection rates are 
all below 100 %. Less than 50 % were exposed to EP and PP, while 88 % were exposed to MP 
(64). The highest detection rates were detected in Wang et al. (21) population of Chinese children. 
Native MP, EP and PP were here detected in all samples (100 %), while BP was discovered in as 
much as 98 % of the samples. Despite low concentrations of parabens in Chinese children, the 
detection rates show almost all of the children were exposed (21). Exposures to also the most 
estrogenic parabens are especially concerning, since children are more sensitive to EDCs than 
adults. However, it is necessary to be aware that unadjusted paraben concentrations in general can 
be affected by differences in each spot sample`s urine volume. Such differences can be related to 
age, pregnancy, medications, kidney disease etc. (105). Differences in unadjusted urine samples 
can make results less comparable, and make it harder to link back to human concentrations and 
effects as compared to blood. Furthermore, in all populations studied, MP was the paraben most 




High concentrations and detection rates of total parabens in urine have been detected in several 
studies (21, 22, 60, 64, 106, 107),  and show widely, but individual human exposures to parabens. 
For instance, the highest GM of MP was observed at a concentration of 140 ng/ml (95 % 
confidence interval (CI) 117, 167) (106), while the lowest GM was 1.53 (range < 0.36 – 59.6) 
ng/ml (22). The highest GM (106) is more than 90 times higher than the lowest value (22). The 
detection rates of MP and PP are over 60 % in all studies assessed. However, when excluding 
Calafat et al. study (107), that only use “over 60 %” and “under 60 %” as a measure for 
percentages of detection, the lowest detection rate of MP and PP are 94 % (64) and 80 % (22), 
respectively. The detection rates of BP and EP differ more than the detection rates of MP and PP. 
The lowest and highest detection rate of BP (10 % and 99 %) was observed in different 
populations in the same study (21). In this study, EP was also detected in all samples (21), while 
two studies did not detect EP at all (60, 106). Less than 100 % detection rate shows that some 
individuals are not exposed. Overall, the observed paraben concentrations differ, but detection 
rates are high.  
When studying exposures to parabens it is also necessary to observe half- life and whether 
parabens accumulate. Several studies have observed a rapid decrease in paraben concentrations 
after administration (20, 97, 98), but Janjua et al. (98) is the only study to investigate paraben half- 
life in humans. Native BP was here shown to reach a mean (SEM) serum concentration of 135 (± 
11) µg/L three hours after the first application. The concentration had decreased to 18 (± 3) µg/L 
24 hours after application. Aubert et al. (20) on the other hand, detected dermally absorbed MP 
and BP to reach maximum concentration after only one hour in male rats. Parabens in the other 
groups reached maximum concentrations after eight hours. Therefore, it is also likely the BP 
concentrations observed by Janjua et al. (98) would have been detected at a much lower level if 
measured earlier than first after 24. However, according to Aubert et al. (20) it is likely the 
maximum concentration reached already after one hour, was caused by a small oral paraben 




parabens measured by Janjua et al. (97) were excreted 8 - 12 hours after exposure, Aubert et al. 
(20) identified paraben excretion 12 - 22 hours after exposure. These results indicate parabens 
have a short half- life in humans as well as in animals, and do not accumulate. Frederiksen et al. 
(108) on the other hand, indicated a possible accumulation of EP and BP in rat amniotic fluid after 
subcutaneous administration of 100, 200 and 400 mg/kg bw/day (108). The measurement was 
however only conducted once after administration, but should have been conducted several times 
to provide evidence of accumulation. More studies have however disproved parabens likelihood to 
accumulate (9, 18, 20, 97, 98).  
In conclusion, evidence show paraben concentrations in general differ among individuals, but 
GMs of native parabens are lower than for total concentrations. High detection rates are observed 
of both native and total parabens. Total levels of MP and PP are detected with both highest GMs 
and detection rates. Literature shows, parabens have a half- life of less than 24 hours and do not 
accumulate, but more human RCTs are warranted. Further research is also needed especially on 
































5.2.1 Vulnerable groups and paraben exposure  
As explained in the background theory, humans have critical windows of developmental 
sensitivity to EDCs (4). Fetuses and children are considered to be the most vulnerable to EDC 
exposures (38), and that is why it is important to study exposures to especially these groups. In 
this chapter, paraben exposures to fetuses and newborns are investigated, by comparing and 
discussing state of the art knowledge.  
The fact that parabens have been detected in human cord blood (109), urine samples from South- 
Korean newborns (110) and in rat placenta, amniotic fluid and whole- body fetuses (108), show 
fetuses can be exposed to parabens. No study, however, exists on paraben exposures to human 
fetuses. As pregnant women have to be exposed to parabens if fetuses are exposed, measurements 
of paraben concentrations and detection rates should be identified to determine the degree of 
exposure to women during pregnancy. Shirai et al. (64) and Meeker et al. (106) are two of the few 
biomonitoring studies primarily investigating parabens in pregnant women. And compared to the 
other studies discussed in chapter five, highest urine concentrations of total MP, PP and EP were 
observed in these studies populations of pregnant women (64, 106). Detection rates of MP, PP and 
BP were observed to be higher by Meeker et al. (106). However, as explained earlier, it is 
important to be aware of possible differences in spot urine volume when comparing unadjusted 
measures. And such differences are likely to be more prevalent when comparing studies of 
pregnant populations, because of increased urine production during pregnancy (105).  
Even though these studies indicate that fetuses can be exposed to parabens through their mothers, 
it has been discussed whether fetuses are better protected from parabens than infants and children 
exposed dermally. This has for instance been suggested by the SCCS (101). The suggestion arises 
from parabens rapid metabolism, and the likelihood of parabens to be metabolized in the mothers’ 
body before reaching the fetus. As one study identified higher concentrations of MP, EP and PP in 




knowledge, no other study comparing levels of dermally applied parabens in newborns or infants 
with their mother`s, only assumptions can be made. The same study also observed MP and PP in 
100 % of the newborns urine samples, EP in 98 % and BP in 41 %. Significant correlations of MP, 
EP and PP were observed between mothers and newborns (110).  But as only medians and 
adjusted measures were shown, estimates cannot be compared with the other studies discussed.  
Even though it is likely that fetuses also get exposed to parabens, one study observed a decrease in 
total paraben concentrations during pregnancy compared to before. GMs was not calculated, but 
medians showed lower paraben concentrations in the second and the third trimester than in the 
first. Within- person GMs, comparing pre- pregnancy measures with pregnancy measures, showed 
higher concentrations of MP, EP and PP in urine before pregnancy than in pregnancy. Spearman’s 
correlations of MP, EP and PP were high (rs = 0.55, rs = 0.56 and rs = 0.55, respectively) (60), 
when interpreted as suggested by Pallant et al. (73). The reductions in paraben concentrations 
during pregnancy can be a result of changes in cosmetic use, but also changes in physiological 
factors has been assumed as a reason. Such physiological factors can be an increased BMI, plasma 
volume expansion and bone mobilization (111). Changes in cosmetic usage patterns can for 
example be related to the use of products especially meant for pregnancy or maternity (creams 
against stretch marks etc.), or it may be caused by a general reduction in the use of cosmetics.  
As both Calafat et al. (107) and Smith et al. (60) observed a higher total level of parabens in 
women’s urine than men`s, potentially unnecessary exposures of the fetus and breastfeeding infant 
are indicated. This can be suggested as women use more cosmetics than men, both in terms of 
frequency and number of products (6, 7). Calafat et al. (107) detected the GM of MP in women to 
be over three times higher than in men (p = < 0.01). But, despite of a wide CI (95 % CI: 80.8, 135) 
in women, the results indicate a much higher exposure among women as men`s CI was much 
lower (95 % CI: 24.8, 35.8). Women had also over six times higher exposure to PP than men 




the GM of MP to be over four times higher in women, while the GM of PP was over seven times 
higher in women than men (p = < 0.1). As the detection rates of MP and PP was observed to be 
quite similar among men and women (60), men are also widely exposed, but at lower 
concentrations. This shows it is possible to reduce paraben exposures in women, and thereby also 
potential exposures of fetuses and infants. Exact percentages of detections above LODs were not 
documented by Calafat et al. (107).  
To decrease paraben exposures can be achieved by reducing the use of cosmetics, or by decreasing 
or removing the paraben content in cosmetic products. Today there are a highly reduced number 
of products for sale containing parabens, and that is likely to be a result of the attention parabens 
have received in media and producers removing parabens from their products. As a consequence, 
paraben exposures could have diminished the last year.  
In conclusion, available studies show stronger evidence of a larger paraben exposure in women in 
general than in men. One study shows paraben exposures in newborns, which is an indication on 
paraben exposures of fetuses or exposures to the newborn. More studies are warranted to 
investigate the extent of exposure to newborns and infants, and whether exposures harm these 





























6. METHODOLOGICAL LIMITATIONS  
There are a number of limitations in studies on parabens that can decrease the reliability of the 
conclusion. It is therefore necessary to present these challenges and reflect upon their possible 
effects on the result.  
The general limitations considered are:  
a) The low number of RCTs; 
b) Small sample size; 
c) Blood/ urine; 
d) Differences among study populations;  
e) Different limit of detection (LOD) levels.  
These limitations are separately explained and reflected upon below: 
a) Low number of RCTs.  
The first and maybe the most important limitation is the lack of RCTs. RCTs are considered the 
“golden standard” in study designs, where strong experimental control is possible; if conducted 
properly. Because of the low number of RCTs and the thesis focus on human studies, more studies 
with observational designs are used. The study designs of papers discussed in chapter 5 (also in 












STUDIES STUDY DESIGN 
Janjua et al. (2007,  2008) (97, 98) Randomized controlled trials (RCTs). Cross- over design 
Fredriksen et al. (2011) (22) Prospective cohort 
Sandanger et al. (2011) (69) Prospective cohort 
Smith et al. (2012) (60) Prospective cohort 
Calafat et al. (2010) (107) Prospective cohort 
Ye et al. (2008) (103) Cross- sectional 
Wang et al. (2013) (21) Cross- sectional 
Shirai et al. (2013) (64) Cross- sectional 
Meeker et al. (2013) (106) Cross- sectional 
               Table 1: Study designs. 
                  
The larger amount of observational studies makes it impossible to study the percentage of 
parabens absorbed, because the dose applied is unknown. And because of parabens short half- life, 
and a time delay between exposure and measurement, it is neither possible to identify the exact 
mean and maximum concentration reached in blood. An example, when a cross- sectional or 
cohort study is conducted to measure native paraben concentrations in serum, the body burden of 
parabens may already have decreased. Another limitation in using an observational design is the 
lack of ability to prove causal relationships. Causality is according to Jekel et al. (112): “a factor 
that produces or contributes to the production of a specified outcome” (p. 383). For instance, a 
causal relationship must be shown between the use of cosmetics and the detection of parabens in 
blood or urine, before evidence of causality can be proven. However, because dermal exposures 
have been shown to be the main route of exposure (14, 64), the discussion have been based on this 
fact. But it is important to have in mind that 4 - 5 % of paraben exposures are estimated to occur 
from an oral route (9, 14). Since the exposure must be proven present before the disease 
(temporality) to show causality (112), cross- sectional studies cannot prove causal relationships. 
The reason is because cross- sectional studies collect information at the same point in time. A 
prospective cohort on the other hand is better showing temporality as subjects are followed over 




is the possible influence of the Hawthorne effect. The Hawthorne effect occur when subjects 
recognize they are observed, and change habits during the study. For instance, such a change can 
be a change in cosmetic use. The different study designs have been ranged in a hierarchy based on 
their abilities to provide evidence of causality (figure 7):  
 
 
Figure 7: The evidence pyramid.  Figure reused with publishers permission (113). 
Designs closer to the top of the pyramid have a larger potential to provide causality. The 
probability of showing causal relationships occur when there is less likelihood of bias, and then 
better internal validity (112). Only systematic reviews and meta- analysis is placed higher than 
RCTs (114). Studies lower than the RCT in the design hierarchy are observational. Observational 
studies are used when an RCT is inappropriate to use. This can for instance be related to ethical or 
medical principles. For example is it both unethical and medically unjustifiably to conduct a RCT 
and apply parabens on pregnant women`s skin to study paraben concentrations in newborns. It is 




Observational designs can in such circumstances be used to investigate associations before a 
potential experimental study. Other factors affecting the choice of study design are cost, time span 
and data availability. A cross- sectional study are simpler and less costly to perform than for 
instance prospective cohorts (112). However, when writing a literature study and there is a lack of 
RCTs, it is common to use animal or in vitro experimental studies instead. The problem of using 
such studies is their lack of external validity. For example is animal studies lower ability to 
extrapolate evidence to humans caused by differences in genetics, nutrition, size, life expectancy 
etc. Animal and in vitro experimental studies can only be used as indications before further studies 
on humans, if possible. Because of the decreased generalizability, both animal- and in vitro 
experiments are placed lower than case series in the evidence pyramid (115).  
Despite observational studies lack abilities to identify dose and causal relationships, and there is a 
time delay between exposure and measurement, the reliability of the thesis conclusion is not 
reduced. Based on the thesis objective, this can be defended by the high detection rates of 
parabens, regardless of study design. The high detection rates show humans are widely and 
regularly exposed to parabens. Observational studies cannot be used to show exact concentrations 
of parabens either, as they have a very short half- life. And neither is it possible to identify 
absorption rates in humans by using observational designs. To identify absorption rates, the 
amount of parabens applied must be known, together with more precise estimates of the absorbed 
parabens than what is possible with observational designs. More human RCTs are therefore 
required. However, a common limitation with the use of RCTs is the false setting they are 
conducted under. A good example of false setting is seen in Janjua et al. (97, 98) studies, where 
unnaturally high amounts of parabens and phthalates were applied on the skin. False settings cause 
less generalizable results. 
In conclusion, despite of the low number of RCTs, high detections of parabens in observational 
studies is evidence enough to prove humans are widely and regularly exposed to parabens. More 




the reduced applicability to humans, animal and in vitro studies can only be used to show 
indications of exposure.  
b) Small sample size  
The studies discussed in chapter 5 vary in sample size. For instance, Calafat et al. (107) has a 
sample size of 2548, while Ye et al. (103) only has 15. Several of the studies have populations of 
less than 70 subjects, and neither of the studies have shown sample size calculations. A small 
sample size can reduce confidence in a study’s results and decrease generalizability.  
A likely reason for small sample sizes in studies on parabens is the cost of analyzing parabens. 
One solution to increase studies power is to use within- subject, cross- over designs as Janjua et al. 
(97, 98). However, the reliability of the thesis conclusion is not affected by the fact that some of 
the studies have low sample size. As every population, regardless of sample size, show high 
detection rates of parabens, prove wide exposures of parabens.  
c) Blood/ urine 
Urine is often the preferred matrix for biomonitoring of chemicals with short– half lives. The 
simplicity of collecting spot urine samples and the fast excretion are two reasons (116). For 
dermally absorbed parabens, blood is preferred. The preference for blood is caused by the fact that 
native parabens better reflect dermal than oral exposures (22), and that native parabens are to a 
larger extent conjugated before excreted in urine. Blood is however also preferred because of 
individual differences in spot urine and unclear definitions of whether it is metabolites, conjugates 
or total levels that have been measured. In urine each void can differ in volume, and therefore also 
in the concentration of chemicals. Adjustments are for this reason often conducted to adjust for 
differences in the volume of spot urine samples (116). If unadjusted values are compared, 




However, despite more studies use urine as matrix than blood, the reliability of the conclusion is 
not reduced. High detection rates of parabens are observed in both blood and urine, but using urine 
as matrix is inadequate for determining the percentage of dose reached, and exposure route. 
Detection rates are neither greatly influenced by whether urine is adjusted or not, as shown by 
Shirai et al. (64). The conclusion of widely occurring paraben exposures is reliable.  
d) Differences among study populations  
The studies discussed in chapter 5, have populations that differ in for instance gender, age and 
origin. Differences therefore exist in the extent of cosmetic use. By comparing findings from 
several different and heterogeneous populations the thesis generalizability increases.  
However, the use of unlike populations may render comparisons, especially if unadjusted 
measures are compared. But as detection rates show the extent of exposures, and high detection 
rates are identified among every population studied, differences among study populations’ do not 
affect the conclusions reliability.  
e) Different limit of detection- levels (LODs) 
As there is different ways to calculate the LOD (19), terms such as LOD, method detection limit 
(MDL), limit of quantification (LOQ) etc. are used. The use of different methods to calculate LOD 
and high percentages below or close to LOD do however reduce comparability. Examples of 
different LOD- levels are observed in the studies by Wang et al. (21) and Shirai et al. (64), where 
LODs were 0.02 ng/ml and 0.47 ng/ml for native EP in urine, respectively. Different methods of 
detection and different LOD- levels are however usually described in the research papers, and can 
therefore be taken into consideration by the assessor. The use of different LOD- levels does not 
decrease the reliability of the thesis conclusion, as high detection rates of parabens can still be and 
are detected. This limitation will only affect comparisons of paraben concentrations detected at 




Finally, the low number of RCTs, studies small sample size, more studies using urine as matrix, 
differences among study populations and the different LOD- levels do not decrease the reliability 
















































7. MIXTURE EFFECTS  
Recently, more focus has been placed on mixture effects of EDCs and the Precautionary Principle. 
The main concern is related to the fact that compounds in combination or mixtures, might elicit 
effects that are not shown for single compounds, or enhance the effects shown for single 
compounds. As evidence is lacking on mixture effects in general, potential risks can be limited by 
enforcing the Precautionary Approach. When the Precautionary Approach enters into force, rapid 
response is permitted to protect human health and the environment. And as it is a fundamental 
principle of environmental law both nationally and internationally, it can be enforced by policy 
makers (17). The Stockholm Conventions framework for instance, is based on the Precautionary 
Approach (117). The principle applies especially to possible threats where significant data is 
lacking (118).  
One study where mixtures of EDCs were shown to increase the overall effect of hormonal 
influences, identified that mixtures of parabens stimulated proliferation of MCF- 7 breast cancer 
cells (83). Even though parabens estrogenic potential or anti- androgenic potential is low by 
themselves (78), they come in addition to the already existing body burden of persistent EDCs 
(see chapter 4.1 on persistent chemicals). Parabens are therefore likely to increase the overall 
effects of estrogenic influences. However, despite of a lack of knowledge on mixture effects, the 
EU considers most parabens safe to use in cosmetics, as long as they are below maximum 
recommended concentrations (86). And as the EUs calculation of MoS do not account for mixture 
effects of parabens in combinations with other EDCs in either children or adults, the likelihood of 
an underestimation of endocrine effects is expected.  
It is however possible for consumers to make choices in order to reduce the number of EDCs they 
are exposed to. One approach is to avoid purchasing EDC- containing cosmetics, but this requires 
knowledge about EDCs. Increased focus and knowledge on parabens among consumers is one 




on that increased awareness and knowledge among consumers can give positive result in reducing 
exposures to EDCs. An easier approach to determine which cosmetics that contain EDCs 
however, are to download the Norwegian Consumer Councils hormone check application for 
iPhones and android mobile devices. The application scans cosmetic products and show whether 
products contain EDCs or not.  
In summary, there is lack of research on mixture effects in general, but potential risks can be 
limited by enforcing the Precautionary Approach. The main concern to mixture effects are related 
to the fact that compounds in combination or mixtures, might elicit effects that are not shown for 
single compounds, or enhance the effects shown for single compounds. As the EUs calculation of 
MoS do not account for mixture effects of parabens, an underestimation of endocrine effects is 
expected. But, it is possible for consumers to make choices in order to reduce the number of EDCs 

















8. CONCLUSION  
Paraben exposures in humans have been studied by discussing and comparing evidence of human 
concentration, dermal absorption, metabolism and excretion. The results show high detection rates 
of native and total parabens in blood and urine, and provide strong evidence of regular or constant 
exposures to widely occurring parabens. Evidence from the literature show a higher cosmetic use 
and higher concentrations of parabens among women than men, and point to cosmetic products 
being responsible for elevated paraben exposures. This is supported by one study that shows 
strong association of elevated paraben levels with cosmetic use. As evidence also point towards 
higher exposures to native parabens if dermally absorbed, dermal exposures are more likely to 
affect health compared to oral exposures.  
Parabens were only used as an example of EDCs in cosmetics, and it is important to be aware that 
there are numerous other EDCs in use. And because the unborn child and breastfeeding infant has 
been identified as sensitive groups to the effects of EDCs and thus parabens, use of EDCs in 
products to pregnant women and mothers with newborns should have special attention. It is 
however possible for consumers to influence the use of parabens and other EDCs in cosmetics. 
One example of the positive effects of caring is the highly reduced number of products for sale 
containing parabens. And this may have reduced exposures to parabens the last year. It is 
nevertheless a need for better knowledge in order to know more about the chemicals in 
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 Matrix 1: Literature matrix of observational human studies reporting parabens in serum and plasma 
Country              n                Population                                                            Median blood paraben concentrations                              Units               Reference 
                      _______________________________________  
                           Native parabens: 
                                                                                                  MP                            EP                           PP                          BP                       
Norway              332             Postmenopausal women
a
             9.4                           < 3                           < 2                             -                     ng/ml           Sandanger et al. (2011) (69)  
                                              Detection rate (%)                       63                              22                             29                                                              
USA                     15             11 women, 4 male
b
                      0.2 (< 0.1–9.8)         < 0.1(< 0.1)             < 0.2 (< 0.2–2.3)       -                      ng/ml          Ye et al. (2008) (103) 
                                              Detection rate (%)                       60                               0                              47                                                              
                 Total parabens (free + conjugated; glucuronidated and sulfated): 
                                                                                                  MP                             EP                            PP                           BP                        
USA                     15             11 women, 4 male
b
                     10.9 (0.4–301)            0.2 (< 0.1–5.4)         1.4 (< 0.2–67.4)        -                     ng/ml         Ye et al. (2008) (103) 
                                              Detection rate (%)                       -                 -                - 
Denmark              60             Healthy, young men
b
                  1.53 (< 0.36–59.6)    < 0.35(< 0.35–20.8)  0.32(< 0.1–5.4)       < 0.33               ng/ml         Frederiksen et al. (2011) (22)                            
                                              Detection rate (%)                      100                                53                            80      
a 






Matrix 2: Literature matrix of observational human studies reporting unadjusted values of parabens in urine 
Country              n                Population (age)                               Geometric mean (GM) urine paraben concentrations                                            Units                        Reference 
                                                                                                      _______________________________________________ 
                                                                                                                                      Native parabens: 
                                                                                                  MP                            EP                           PP                           BP                       
USA                  40              Children 3-10a                              0.32 (< 0.3–8.74)       NA                          NA                          NA                                         ng/ml    Wang et al. (2013) (21) 
                                            Detection rate (%)                        78                              33                            48                            8 
China                70              Children 9–10a                              1.00 (0.29–11.0)        0.19 (0.03–5.56)      0.32 (0.10–4.25)     0.01 (0.004–0.03)                  
                                            Detection rate (%)                        100                            100                          100                           98 
                          26              Adultsa                                           3.15(< 0.03–312)      NA                          0.46 (< 0.03–119)    NA 
                                            Detection rate (%)                         92                              46                            92                             23  
Japan                111             Pregnant womenb                          6.99 (< 0.57–544)     0.62 (< 0.47-63.2)   0.60 (< 0.48–14.3)     -                                          ng/ml    Shirai et al. (2013) (64) 
                                            Detection rate (%)                         88                              49                            46                                                            
         Total parabens (free + conjugated; glucuronidated and sulfated): 
                                                                                                  MP                             EP                            PP                           BP                        
Japan                  111           Pregnant womenb                       62.6 (<0.57-1361)       5.59 (<0.47-593)     19.7 (<0.48-2690)   0.89 (0.46-22.8)                    µg/L     Shirai et al. (2013) (64) 
                                            Detection rate (%)                      94                                81                             89                            54 
Denmark             60            Healthy, young menb                  1.53 (< 0.36–59.6)     < 0.35(< 0.35–20.8)  0.32 (< 0.1–5.4)     < 0.33                                     ng/ml    Frederiksen et al. (2011) (22)               






USA                   40             Children 3-10a                            62.4 (3.30–4510)       0.10 (<0.02-2.69)      0.92 (<0.03-365)   <0.02 (<0.02-0.48)                  ng/ml   Wang et al. (2013) (21)       
                                           Detection rate (%)                        100                            60                             83                            10 
China                70             Children 9–10a                              5.28 (0.85–54.7)        0.97 (0.11–31.7)      1.89 (0.24–71.5)      0.04 (<0.02–0.41)                  
                                           Detection rate (%)                        100                            100                           100                           99 
                          26             Adultsa                                          30.5 (1.85–3420)       0.34 (<0.02-119)     5.07 (0.07–515)       NA (<0.02-11.0) 
                                           Detection rate (%)                        100                             50                            100                           35 
Puerto Rico       105           Pregnant womenc                          140 (117,167)             -                              30 (24.1-37.5)         1.0 (0.8-1.3)                             ng/ml    Meeker et al. (2013) (106) 
                                           Detection rate (%)                        100                              -                              99.3                         58.4            
 USA                 653           Male and females (mean 36)b       100 (<1- 23,200)         -                              17.9 (<0.2-2870)     1.08 (<0.2-998)                       µg/L    Smith et al. (2012) (60) 
                                           Detection rate (%)                        99.7                             -                              96.5                          65.4 
USA                 2548          Male and females (>6)c                56.4 (46.9-97.9)         <0.01 (<0.01)          7.91 (6.41-9.77)        Male: NA                                µg/L    Calafat et al. (2010) (107)               
                                                                                                                                                                                                      Women:0.904 (0.760-1.07)                       
                                           Detection rate (%)                        >60                            <60                          >60                          <60 
a 5th-95th percentile  b range (minimum- maximum) c 95 % CI 
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